Overview

Recombinant Human Endostatin Adenovirus Combined With Chemotherapy for Advanced Head and Neck Malignant Tumors

Status:
Unknown status
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
This study will investigate the efficacy and safety of recombinant human endostatin adenovirus combined with chemotherapy for advanced head and neck malignant tumors.
Phase:
Phase 2
Details
Lead Sponsor:
Renmiao Zhang
Collaborator:
West China Hospital
Treatments:
Albumin-Bound Paclitaxel
Cisplatin
Endostatins
Paclitaxel